Overview

Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with severe chronic obstructive pulmonary disease (COPD).

Phase:

Phase 4

Details

Lead Sponsor:

AstraZeneca

Treatments:

Budesonide
Budesonide, Formoterol Fumarate Drug Combination
Formoterol Fumarate
Tiotropium Bromide